Table 1 Summary of IgAN cases in haematological malignancy patients
Paper | Gender | Age (years) | Location | IgAN timing relative to malignancy Sx | Malignancy | Stage | SCr | Proteinuria | Haematuria | Serum IgA level | Kidney biopsy | Malignancy treatment | Renal recovery post malignancy treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Motoyama 2008 [10] | F | 5 | JPN | 5 years post | ALL (undifferentiated) | NA | Normal | Present | Macro | Elevated | Crescents, mesangial proliferation, mesangial IgA deposits | Prednisolone, vincristine, methotrexate, 6-MP | No – recurrent microhaematuria w/o persistent proteinuria |
Iwata 2006 [18] | M | 28 | JPN | 8 years prior | ALL (undifferentiated) | NA | 53 μmol/L | 3 g/day | Micro | Normal | Glomerulosclerosis, mild mesangial proliferation, mesangial IgA deposits | Prednisolone, vincristine, daunorubicine, etoposide, mitoxantrone, cytarabine, methotrexate, peripheral stem cell transplantation | Yes – proteinuria decreased to 0.5 g/day at 16 months post CTx |
Bergmann 2005 [9] | F | 60 | DEU | 4 weeks post | Hodgkin lymphoma (mixed cellularity) | IIIA | 681 μmol/L | 2.3 g/day | Micro | Elevated | Crescents, diffuse mesangial proliferation, mesangial IgA deposits | Prednisolone, cyclophosphamide, etoposide, bleomycin, doxorubicin, vincristine, procarbazine | Yes – SCr, proteinuria within normal range |
Khositseth 2007 [16] | M | 14 | THA | 6 months post | Hodgkin lymphoma (nodular sclerosing) | IIIE | 80 μmol/L | 0.8 g/day | Micro | NR | Glomerulosclerosis, diffuse mesangial proliferation, mesangial IgA deposits | Cyclophosphamide, vincristine, doxorubicin, prednisolone | Yes – proteinuria normalized, urine RBC < 50/HPF |
Cherubini 2001 [15] | M | 44 | ITA | 1 year post | Hodgkin lymphoma (nodular sclerosing) | IV | 354 μmol/L | 4 g/day | Micro | Elevated | Crescents, mesangial IgA deposits | Prednisolone, nitrogen mustards, oncovin, procarbazine, adriamycin, bleomycin, vinblastine, dacarbazine | Yes – SCr within normal limits |
Harada 2017 [11] | M | 79 | JPN | Same | Angioimmunoblastic T-cell lymphoma | IV | 159 μmol/L | 1.5 g/day | Micro | Elevated | Mesangial IgA deposits, lymphoma invasion | Prednisolone, cyclophosphamide, pirarubicine, vincristine | Yes – SCr, proteinuria, haematuria within normal range |
Moe 1993 [13] | F | 66 | USA | 6 months post | Mycosis fungoides | IV | High | 1.0 g/day | Macro | NR | Crescents, diffuse mesangial proliferation, mesangial IgA deposits | Psoralen-ultraviolet A, allopurinol | No-IgAN presented after failed treatment |
Ramirez 1981 [14] | M | 70 | USA | 1 year post | Mycosis fungoides | IV | 177 μmol/L | NR | Micro | NR | Glomerulosclerosis, mesangial proliferation, mesangial IgA deposits | NR | NR |
Ramirez 1981 [14] | M | 56 | USA | 3 years post | Mycosis fungoides | IV | Normal | NR | Micro | NR | Focal mesangial proliferation, mesangial IgA deposits | NR | NR |
Motoyama 2008 [10] | M | 12 | JPN | 3 years prior | Diffuse medium-sized B cell lymphoma | II | Normal | NR | Micro | Normal | Mild mesangial proliferation, mesangial IgA deposits | Prednisolone, cyclophosphamide, epirubicine, methotrexate, etoposide, cytarabine | No-recurrent macrohaematuria w/o persistent proteinuria |
Mak 1998 [17] | M | 62 | HKG | Same | MALT B-cell lymphoma | IV | 309 μmol/L | 4.1 g/day | Macro | Elevated | Glomerulosclerosis, diffuse mesangial proliferation, mesangial IgA deposits, lymphoma invasion | Chlorambucil | Yes – SCr, proteinuria, haematuria within normal limits |
Forslund 2007 [19] | M | 76 | FIN | 5 years post | Multiple myeloma | III | 752 μmol/L | 4.0 g/day | Micro | Low | Mesangial proliferation, mesangial IgA deposits | Prednisolone, vincristine, cyclophosphamide, melphalan, adriamycin, dexamethasone, thalidomide, bortezomib | Yes – SCr 168 μmol/L 1 month post-treatment |